MIRA PHARMACEUTICALS, INC. - 8-K Filing

Mira Pharmaceuticals advances Ketamir-2 to Phase 2a in CIPN following FDA review (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Other Exhibits)

SEC EDGAR ·

Tickers: $MIRA

Read the full article at SEC EDGAR

More Regulatory news